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Abstract
Background: Increasingly, breast cancer patients undergo bilateral mastectomy (BLM). The 
magnitude of benefit is unknown.
Methods: We used SEER data on all women diagnosed in California from 1998-2015 with stage 
0-III unilateral breast cancer and treated with BLM versus breast conserving therapy including 
surgery and radiation (BCT) or unilateral mastectomy (ULM). We measured relative risks of 
second contralateral breast cancer (CBC) and breast cancer death using Fine and Gray 
multivariable regression modeling adjusted for the competing risk of death and death from another 
cause, respectively, and potential confounding factors. We measured absolute excess risk (AERs) 
of CBC as the observed minus expected number of breast cancers in the general population, 
divided by 10,000 person-years at risk.
Results: Among 245,418 patients with median follow-up of 6.7 years, 7,784 (3.2%) developed 
CBC. Relative risks were lower after BLM (hazard ratio (HR) 0.10, 95% confidence interval 
0.07-0.14) and higher after ULM (HR 1.07, 1.02-1.13) versus BCT. AERs were higher after BCT 
and ULM (5.0 and 13.6 more cases, respectively) than BLM (28.6 fewer cases). BLM reduced risk 
more for older women (38.0 fewer cases for age≥50, versus 17.9 among age<50) but provided 
similar risk reduction across categories of grade and tumor hormone receptor status. Compared to 
BCT, risk of breast cancer death was equivalent after BLM (HR 1.03, 0.96-1.11) and higher after 
ULM (HR 1.21, 1.17-1.25).
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Conclusions: BLM may reduce second breast cancer risk by 34-43 cases per 10,000 person-
years compared to other surgical procedures but is not associated with lower risk of death. Second 
breast cancers are rare, and their reduction should be weighed against harms associated with BLM.
Precis (Condensed Abstract):
Data from the population-based California Cancer Registry were used to estimate the magnitude 
of benefit from bilateral mastectomy among 245,418 breast cancer patients: compared to other 
surgical treatments, bilateral mastectomy reduces second contralateral breast cancer risk by 34-43 
cases per 10,000 person-years. However, second breast cancers are rare and their prevention 
should be weighed against the harms associated with bilateral mastectomy.
Keywords
breast cancer; second contralateral breast cancer; bilateral mastectomy; cancer prevention; 
absolute excess risk
INTRODUCTION
The use of bilateral mastectomy (BLM) as a primary treatment for unilateral breast cancer 
has risen in the United States (U.S.) population, even though several clinical trials and 
observational studies demonstrate no survival benefit from this invasive procedure.1-3 BLM 
is uncommon outside of the U.S. Moreover, BLM has greater morbidity than unilateral 
mastectomy (ULM) or breast conserving surgery with radiation (breast conserving therapy, 
BCT), in terms of complications, body image, recovery time and impact on employment.4-8
The choice to undergo BLM is complex. Although the probability of developing a 
contralateral, second breast cancer has declined in the U.S. over time9, potentially due to 
more widespread use of adjuvant endocrine therapy10, most patients report that fear of a 
subsequent breast cancer was their primary motivation for choosing BLM.11 Prior studies 
have reported that BLM confers a relative risk reduction in range of 90-95% for second 
contralateral breast cancers among patients with a personal and family history of breast 
cancer.12-15 However, there is no population-based evidence regarding the absolute 
reduction in second contralateral breast cancer risk conferred by BLM, particularly in patient 
subgroups defined by specific demographic and tumor characteristics. A better 
understanding of the effectiveness and absolute risk reduction from BLM across patient 
subgroups may guide shared decision-making among women with breast cancer and their 
surgeons.
Leveraging the large, diverse population of California, we used data from the population-
based California Cancer Registry (CCR) to estimate: the risks of second contralateral breast 
cancers, risks of breast cancer-specific death, and absolute excess risks (relative to the 
general population) among women with stage 0-III breast cancer treated with BLM versus 
other surgical procedures from 1998-2015.
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METHODS
The study population comprised all women residing in California when diagnosed with a 
first primary breast cancer (International Classification of Disease for Oncology, third 
edition, site codes C.50.0-50.9; histologic codes: 8000, 8010, 8020, 8022, 8050, 8140, 
8201-8230, 8255, 8260, 8401, 8453, 8480-8525, and 8575) of American Joint Committee on 
Cancer (AJCC) stages 0-III between January 1, 1998 (study start date) and December 31, 
2015 (study end date). Human subjects approval was covered under the Greater Bay Area 
Cancer Registry protocol approved by the Institutional Review Boards of the Cancer 
Prevention Institute of California and the University of California, San Francisco.
Information from the CCR included demographic and clinical characteristics, tumor 
features, initial treatment course, occurrence of a subsequent ipsilateral or contralateral 
breast cancer, vital status and cause of death as of December 31, 2015. Patients with 
subsequent ipsilateral cancers after more than six months were censored at the time of that 
event, as it is possible that these were in-breast tumor recurrences rather than second 
primary breast cancers. Only contralateral breast cancers (invasive or in-situ) were 
categorized as second breast cancers for the purpose of this analysis. To focus primarily on 
sequential rather than concurrent breast tumors, we excluded second breast tumors that were 
diagnosed less than six months after the first breast cancer diagnosis. In addition, we 
excluded women whose surgery occurred over six months after the initial diagnosis. Second 
tumors reported in the first six months after the initial diagnosis may have been diagnosed 
before the treatment surgery or may represent incidental diagnoses made on review of 
surgical pathology rather than true primaries. Surgeries more than 6 months after the initial 
diagnosis may reflect disease progression or recurrence, not treatment of the primary tumor. 
Patients were eligible for inclusion in the study if they had received one of four surgical 
treatments consistent with clinical practice guidelines within 6 months of the initial 
diagnosis: bilateral mastectomy (BLM), unilateral mastectomy (ULM), breast conserving 
treatment consisting of breast conserving surgery (BCS) with radiation (BCT),16 and in 
women of age ≥70 years with stage I, hormone receptor-positive and HER2-negative breast 
cancer, BCS without radiation was also included as this treatment is consistent with practice 
guidelines for such patients.16 Women who received non guideline-concordant surgical 
treatment were excluded from the analysis as they were considered non-representative of the 
standard of care. Neighborhood socioeconomic status (nSES) was measured by patients’ 
residential census block group at diagnosis using an established multi-component scale.17 
Patient subgroups of fewer than five people are reported as n<5 to preserve patient 
anonymity, in accordance with practices of the CCR.18 Tumors were considered estrogen 
receptor (ER) and progesterone receptor (PR)-negative if both receptors were negative. 
Tumors were considered ER and/or PR-positive if either receptor was positive.
We estimated associations with second contralateral breast cancer risk among patients 
undergoing BCT compared to those receiving other treatments using a Fine and Gray 
competing risk regression model, with follow-up beginning six months after the initial 
diagnosis. We selected Fine and Gray as the primary analytic method because it employs a 
multivariable model that reduces bias due to informative censoring. This method estimates 
the hazard rate ratio (HR) and 95% confidence intervals (CI) by modeling the hazard of the 
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cumulative incidence function while controlling for the competing risk of death and 
adjusting for the variables in Table 1 as potential confounders. We used Fine and Gray 
regression to estimate associations with the risk of breast cancer death, controlling for the 
competing risk of death from other causes, among patients undergoing BCT compared to 
those receiving other treatments,19-21 and used Cox regression to estimate associations with 
risk of death from all causes.
The proportional hazards assumption was tested for all three outcomes using Cox regression 
by examining the correlation between time and scaled Schoenfeld residuals for surgical 
procedure and all covariates. The proportional hazards assumption was not violated for the 
subsequent contralateral breast cancer outcome, but was violated for the breast cancer-
specific mortality outcome for stage, tumor size, grade, and ER/PR status and for all-cause 
mortality for age, stage, tumor size, lymph node involvement, grade and ER/PR status. 
When stage was included as an underlying stratifying variable in the Cox breast cancer-
specific mortality model, additionally stratifying by tumor size and diagnosis year changed 
the HR for the main effect of surgical procedure somewhat, but additionally stratifying by 
tumor grade or by ER/PR status did not. Thus, stage (0, I, II, III), tumor size (<1.0, 1.0-1.9, 
2.0-2.9, 3.0-4.9, >5.0 cm) and diagnosis year (1998-2003, 2004-2009, 2010-2015) were 
included as underlying stratifying variables in the fully adjusted Fine and Gray mortality 
models, which allowed the baseline hazard to vary by these factors, but tumor grade and 
ER/PR status were simply adjusted for in fully adjusted models. For all-cause mortality, age 
and stage were included as underlying stratification variables in the fully adjusted Cox 
regression model, and the other factors were simply adjusted for as stratifying by them did 
not change the main effect. Wald tests for interaction between surgical procedure and age, 
grade, and ER/PR status were computed using cross-product terms in models adjusted for all 
statistically significant (p<0.05) interactions with the stratification variable.
Based on evidence that absolute risk estimates are most easily understood and useful for 
patient decision-making22,23, we calculated absolute excess risk (AER) of a second 
contralateral breast cancer as the number of observed breast cancer cases minus the expected 
number of incident breast cancers for the general California population. The expected 
number was calculated by multiplying age group- and calendar period-specific breast cancer 
incidence rates for California women by the corresponding person-years of follow-up in our 
cohort in jointly defined 5-year age groups and 3-year calendar periods and summing over 
all groups. The difference between the number of observed minus expected breast cancer 
cases was divided by person-years at risk (py). We presented AER estimates per 10,000 py.
All analyses were performed in SAS version 9.4 (SAS Institute, Inc, Cary, NC) and all 
statistical tests were two-sided. P<0.05 was used to denote statistical significance and no 
adjustment was made for multiple comparisons.
RESULTS
A total of 421,643 women were diagnosed with a first primary breast cancer in California 
from 1998-2015. Patients were excluded from analysis hierarchically as follows: age at 
diagnosis <20 years (n=37); AJCC stage other than 0-III (n=35,057); diagnosis by death 
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certificate or autopsy only (n=43) or diagnosis not microscopically confirmed (n=278); 
ineligible histologic type (n=5,652); tumor size unknown (n=19,739), no tumor noted 
(n=445), microscopic (n=6,576), diffuse (n=854), Paget’s disease (n<5) or mammographic 
diagnosis only (n=1,209); unknown nodal status (n=1,986); surgery other than ULM, BLM 
or BCT except among women age ≥70 years with stage I, ER/PR-positive and HER2-
negative breast cancer (n=59,602 having lumpectomy without radiation and not meeting the 
age, stage, ER/PR and HER2 criteria above; n=8,912 no surgery, other surgery or not 
otherwise specified; and n=51 with unknown surgery); date of surgery >6 months after 
initial diagnosis (n=11,404); unknown surgery date (n=5,190); bilateral tumors at initial 
diagnosis (n=11); subsequent breast tumor <6 months after the first tumor (n=8,187); 
follow-up <6 months (n=10,991). After exclusions, 245,418 women remained, of whom 
7,784 (3.2%) developed a contralateral second breast cancer more than 6 months after 
diagnosis of their first breast cancer. Median follow-up time was 6.7 years.
Of 245,418 women analyzed, 127,766 (52.1%) underwent BCT, 92,062 (37.5%) underwent 
ULM and 18,575 (7.6%) underwent BLM. There were 7,015 women (2.9%) of age ≥70 with 
stage I, ER/PR-positive, HER2-negative disease who received BCS without radiation. Most 
patients undergoing BCT were in stages 0-I (71.0%), compared to ULM (40.7%) and BLM 
(51.7%) (Table 1).
Compared to BCT recipients in a Fine and Gray multivariable-adjusted model (Table 2), 
BLM recipients had significantly lower risk of contralateral breast cancer (HR 0.10, 95% CI 
0.07-0.14) while ULM recipients had higher risk (HR 1.07, 1.02-1.13) and BCS without 
radiation recipients (aged ≥70 with stage I, ER/PR-positive, HER2-negative disease) had 
equivalent risk (HR 0.91, 0.77-1.08). Results were similar in a model minimally adjusted for 
age and stage (BLM HR 0.10, 95% CI 0.07-0.13; ULM HR 1.10, 95% CI 1.05-1.15; BCS 
HR 0.85, 95% CI; 0.71-1.00). Stratified analyses in multivariable-adjusted models showed 
similar risk reductions associated with BLM in younger and older women (age <50: HR 
0.09, 0.05-0.15, versus age ≥50: HR 0.11, 0.07-0.18; p-interaction for BLM=0.48) and by 
hormone receptor status (ER/PR-negative: HR 0.13, 0.07-0.23, versus ER/PR-positive: HR 
0.09, 0.06-0.15; p-interaction for BCS=0.35), and greater risk reduction in those with lower 
grade (grade 1-2: HR 0.07, 0.04-0.13, versus grade 3: HR 0.14, 0.09-0.22; p-interaction for 
BLM=0.03). Supplemental Figure 1 shows unadjusted Cumulative Incidence Function plots 
for contralateral breast cancer development by surgical procedure stratified by age and 
hormone receptor status, which control for the competing risk of death.
AER of second contralateral breast cancer differed among surgical procedures (Table 3). 
BLM recipients had 28.6 fewer cases per 10,000 py compared to the general California 
population, while BCT recipients had 5.0 more cases and ULM recipients had 13.6 more 
cases. AER reduction after BLM was somewhat greater for women aged ≥50 years at initial 
diagnosis (38.0 fewer cases per 10,000 py) versus <50 years (17.9 fewer cases), with lower-
grade (31.4 fewer cases) versus higher-grade tumors (23.9 fewer cases), and with ER/PR-
positive (29.5 fewer cases) versus ER/PR-negative tumors (23.4 fewer cases). AER increases 
were notable in BCT recipients aged <50 (21.2 more cases per 10,000 py), with grade 3 
(11.3 more cases) or ER/PR-negative tumors (19.2 more cases), with a similar pattern after 
ULM.
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Compared to BCT recipients in a Fine and Gray multivariable-adjusted model (Table 4), 
BLM recipients had a similar risk of breast cancer death as BCT recipients (HR 1.03, CI 
0.96-1.11). Risk of breast cancer death was slightly higher among ULM recipients (HR 1.21, 
1.17-1.25) and recipients of BCS without radiation who were age ≥70 with stage I, ER/PR-
positive, HER2-negative disease (1.36, 1.16-1.59). Risk of breast cancer death was 
statistically significantly associated with all factors included in the multivariable model 
(Table 4). Supplemental Figure 2 shows unadjusted Cumulative Incidence Function plots for 
breast cancer death by surgical procedure stratified by age and hormone receptor status, 
which control for the competing risk of death from other causes. Similarly for all-cause 
mortality, compared to BCT, risk was increased for ULM and BCS, but was similar for BLM 
(BLM HR 0.98, 95% CI 0.93-1.04; ULM HR 1.36, 95% CI 1.33-1.39; BCS HR 2.24, 95% 
CI 2.14-2.35).
DISCUSSION
We took advantage of the large, diverse, population-based California Cancer Registry to 
examine associations with second contralateral breast cancer and estimate the number of 
breast cancers potentially prevented by BLM. Among more than 240,000 patients diagnosed 
with unilateral breast cancer over a 18-year period, 3.2% developed a second contralateral 
breast cancer. The absolute excess risk reduction after BLM was 29 fewer cases of second 
contralateral breast cancer per 10,000 py, versus an excess risk of five more cases after BCT. 
This can be interpreted as an absolute difference of 34 fewer cases per 10,000 py at risk after 
BLM compared to BCT. Similarly, we estimated an excess risk of 14 more cases after ULM, 
or an absolute difference of 43 fewer cases per 10,000 py at risk after BLM compared to 
ULM. Notably, our results confirm those of several prior analyses24-29, including our own1, 
that found no improvement in the risk of death from breast cancer associated with BLM 
versus BCT. One possible explanation is that breast cancer survivors undergo more intensive 
secondary surveillance than before their diagnosis, and thus a second contralateral breast 
cancer is likely to be discovered at an earlier, more curable stage – and thus the risk of death 
from breast cancer is more likely to be determined by the first breast cancer diagnosis than 
by the second. Another possibility is unmeasured confounders in surgical treatment 
selection, which might result in patients with worse-prognosis tumors being more likely to 
receive BLM than BCT. Regardless of its cause, the repeatedly demonstrated absence of a 
survival benefit associated with BLM should be a crucial consideration in any discussion 
about BLM for secondary cancer prevention.
Importantly, our results join those of earlier studies in offering reassurance that second 
contralateral breast cancer is uncommon.30 Previous studies have shown that second 
contralateral breast cancer incidence varies according to patient characteristics, with greater 
risk reported among younger women with ER/PR-negative tumors.31-34 This likely reflects 
the higher prevalence of hereditary pathogenic variants in BRCA1/2 and other DNA repair 
genes within this patient sub-population33-36; however, a recent study also reported a high 
risk of second contralateral breast cancers among women with a family history of breast 
cancer, even when genetic testing was negative.37 Unlike survivors of ER/PR-positive 
cancers, ER/PR-negative survivors do not take adjuvant endocrine therapy that has the 
beneficial side effect of reducing their risk of a second breast cancer.38 As in prior 
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studies30,32-34,37, we found a significant increase in second breast cancer risk among women 
aged <50 years at initial diagnosis and/or with ER/PR-negative disease. These findings are 
consistent with clinical practice guidelines that advise genetic counseling and testing among 
women diagnosed at age <50 years or with triple-negative breast cancer.39
Our absolute excess risk estimates enable comparison of surgical options. For example, our 
AER estimate for ER/PR-negative survivors suggests 19 (for BCT) or 28 (for ULM) more 
second contralateral breast cancers per 10,000 py (compared to the population average), 
versus 23 fewer cases after BLM: this might be interpreted as 42 or 51 fewer second 
contralateral breast cancers after BLM compared to BCS or ULM. With ER/PR-positive 
disease, the difference is more modest, at 31 or 38 fewer second contralateral breast cancers 
after BLM compared to BCS or ULM. However, caution is needed in extrapolating 
aggregate data to individuals. Moreover, patients differ in numeracy and in the valence they 
place on risk estimates. What one patient might consider a negligible benefit of BLM, 
weighed against its potential harms of greater pain, recovery time, impact on body image 
and employment,4-6 might seem worthwhile to another. These estimates can help benchmark 
the benefits of BLM according to patient characteristics.
Our study has some limitations. Most importantly, we cannot discount the possibility that the 
observed risk reductions may reflect confounding. We adjusted for available known 
confounders for contralateral breast cancer development and breast cancer death using a 
Fine and Gray multivariable regression model. However, we cannot exclude the influence of 
unmeasured confounders, particularly inherited cancer susceptibility. Since SEER does not 
routinely collect germline genetic testing information, we could not distinguish pathogenic 
variant carriers who might benefit most from BLM, and this is a limitation of the study. 
Ongoing efforts to link genetic testing data to SEER records should facilitate re-evaluation 
of this question in the future.40,41 Another limitation is the relatively short median follow-up 
time of 6.7 years. Our study focused on women with first primary breast cancers but it is 
possible that these women differ from those who pursue BLM after diagnosed with a second 
or third primary breast cancer. Our AER estimates are based on a standardized incidence 
ratio approach that compares to breast cancer rates in the general population, which is an 
accepted way to derive such estimates31,42 but are not adjusted for confounders other than 
age and calendar year, and differ from the Fine and Gray method we used elsewhere in this 
study. While the study sample size was very large, it is still possible that smaller, possibly 
important differences may not have been detected. P<0.05 was used to denote statistical 
significance and no adjustment was made for multiple comparisons; the chance of falsely 
rejecting a null hypothesis may exceed 0.05. The study is limited to California and may not 
fully represent other populations. However, the study’s notable strengths include the size and 
diversity of California’s population and a registry that is stringently audited for quality.
Implications for Patient Care
Among breast cancer patients, BLM is estimated to reduce the risk of developing a second 
contralateral breast cancer substantially compared to BCT or ULM, and to a level well 
below the average woman’s risk of developing a first breast cancer. However, there is no 
evidence that BLM reduces the risk of death from breast cancer. Second contralateral breast 
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cancers are uncommon and the absolute risk reduction with BLM varies according to patient 
age and tumor characteristics. Absolute risk estimates are often more comprehensible to 
patients, and their presentation is recommended.22,23 These results may be used to guide 
shared decision-making about the surgical prevention of second contralateral breast cancers.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Table 1.
Patient and tumor characteristics among 245,418 breast cancer patients of stages 0-III, 1998-2015, California
Surgical Procedures
All Patients
Breast conserving
surgery without
radiation (in
patients aged ≥70,
stage I, ER/PR-
positive, and
HER2-negative)
Breast conserving
therapy (surgery
with radiation)
Unilateral
mastectomy
Bilateral
mastectomy
N
Column 
% N
Column 
% N
Column 
% N
Column 
% N
Column 
%
All 7,015 100.0 127,766 100.0 92,062 100.0 18,575 100.0 245,418 100.0
Race/Ethnicity
Non-Hispanic (NH) 
White 5,510 78.5 87,149 68.2 53,920 58.6 13,171 70.9 159,750 65.1
NH Black 311 4.4 6,964 5.5 5,271 5.7 721 3.9 13,267 5.4
Hispanic 698 10.0 18,448 14.4 17,196 18.7 2,662 14.3 39,004 15.9
Chinese 112 1.6 3,773 3.0 3,773 4.1 366 2.0 8,024 3.3
Japanese 111 1.6 1,774 1.4 1,367 1.5 172 0.9 3,424 1.4
Filipina 100 1.4 4,260 3.3 5,124 5.6 612 3.3 10,096 4.1
Other Asian/Pacific 
Islander 105 1.5 4,414 3.5 4,681 5.1 698 3.8 9,898 4.0
Other or unknown 68 1.0 984 0.8 730 0.8 173 0.9 1,955 0.8
Age at diagnosis, 
years
<40 - - 4,407 3.4 5,541 6.0 2,470 13.3 12,418 5.1
40-49 - - 22,195 17.4 18,138 19.7 6,227 33.5 46,560 19.0
50-64 - - 54,188 42.4 32,792 35.6 7,101 38.2 94,081 38.3
≥65 7,015 100.0 46,976 36.8 35,591 38.7 2,777 15.0 92,359 37.6
Marital status at 
diagnosis
Unmarried 3,925 56.0 47,126 36.9 37,489 40.7 5,954 32.1 94,494 38.5
Married 2,838 40.5 77,404 60.6 52,012 56.5 12,173 65.5 144,427 58.8
Unknown 252 3.6 3,236 2.5 2,561 2.8 448 2.4 6,497 2.6
Neighborhood 
socioeconomic 
status (SES), 
quintiles
First (lowest) 
quintile 675 9.6 11,561 9.0 12,638 13.7 1,313 7.1 26,187 10.7
Second quintile 1,156 16.5 19,109 15.0 17,164 18.6 2,467 13.3 39,896 16.3
Third quintile 1,479 21.1 25,536 20.0 19,445 21.1 3,480 18.7 49,940 20.3
Fourth quintile 1,754 25.0 31,676 24.8 21,199 23.0 4,717 25.4 59,346 24.2
Fifth (highest) 
quintile 1,951 27.8 39,884 31.2 21,616 23.5 6,598 35.5 70,049 28.5
Insurance status
No insurance 17 0.2 798 0.6 799 0.9 123 0.7 1,737 0.7
Private only 2,111 30.1 81,644 63.9 53,931 58.6 14,549 78.3 152,235 62.0
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Surgical Procedures
All Patients
Breast conserving
surgery without
radiation (in
patients aged ≥70,
stage I, ER/PR-
positive, and
HER2-negative)
Breast conserving
therapy (surgery
with radiation)
Unilateral
mastectomy
Bilateral
mastectomy
N
Column 
% N
Column 
% N
Column 
% N
Column 
% N
Column 
%
Medicare with or 
without private 4,109 58.6 27,606 21.6 20,437 22.2 1,989 10.7 54,141 22.1
Any Medicaid, 
military or other 
public 707 10.1 13,283 10.4 15,045 16.3 1,605 8.6 30,640 12.5
Unknown 71 1.0 4,435 3.5 1,850 2.0 309 1.7 6,665 2.7
Stage
0 - - 19,545 15.3 9,436 10.2 3,022 16.3 32,003 13.0
I 7,015 100.0 71,106 55.7 28,044 30.5 6,570 35.4 112,735 45.9
II - - 33,906 26.5 40,242 43.7 6,578 35.4 80,726 32.9
III - - 3,209 2.5 14,340 15.6 2,405 12.9 19,954 8.1
Tumor size, 
centimeters
<1 2,785 39.7 34,934 27.3 11,883 12.9 3,450 18.6 53,052 21.6
1.0-1.9 3,878 55.3 56,678 44.4 25,909 28.1 5,692 30.6 92,157 37.6
2.0-2.9 352 5.0 23,845 18.7 21,802 23.7 4,032 21.7 50,031 20.4
3.0-5.0 0 0.0 10,729 8.4 22,173 24.1 3,480 18.7 36,382 14.8
>5 0 0.0 1,580 1.2 10,295 11.2 1,921 10.3 13,796 5.6
Tumor grade
Grade 1 3,195 45.5 32,781 25.7 14,553 15.8 3,142 16.9 53,671 21.9
Grade 2 3,047 43.4 53,449 41.8 36,893 40.1 7,555 40.7 100,944 41.1
Grade 3 554 7.9 36,376 28.5 35,575 38.6 6,981 37.6 79,486 32.4
Unknown 219 3.1 5,160 4.0 5,041 5.5 897 4.8 11,317 4.6
Tumor histology
Ductal 5,758 82.1 110,403 86.4 78,103 84.8 15,500 83.4 209,764 85.5
Lobular 579 8.3 7,866 6.2 8,793 9.6 2,162 11.6 19,400 7.9
Other 678 9.7 9,497 7.4 5,166 5.6 913 4.9 16,254 6.6
Estrogen/
progesterone 
receptors (ER/PR)
Both negative - - 15,923 12.5 16,025 17.4 2,956 15.9 34,904 14.2
Either positive 7,015 100.0 101,100 79.1 65,036 70.6 14,250 76.7 187,401 76.4
Unknown or 
borderline - - 10,743 8.4 11,001 11.9 1,369 7.4 23,113 9.4
HER2 status
Negative 7,015 100.0 76,400 59.8 48,090 52.2 11,254 60.6 142,759 58.2
Positive - - 12,527 9.8 13,435 14.6 2,580 13.9 28,542 11.6
Unknown or 
borderline - - 38,839 30.4 30,537 33.2 4,741 25.5 74,117 30.2
Cancer. Author manuscript; available in PMC 2021 March 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Kurian et al. Page 13
Surgical Procedures
All Patients
Breast conserving
surgery without
radiation (in
patients aged ≥70,
stage I, ER/PR-
positive, and
HER2-negative)
Breast conserving
therapy (surgery
with radiation)
Unilateral
mastectomy
Bilateral
mastectomy
N
Column 
% N
Column 
% N
Column 
% N
Column 
% N
Column 
%
Lymph node 
involvement
Negative - - 105,130 82.3 54,443 59.1 12,234 65.9 178,777 72.8
Positive - - 22,636 17.7 37,619 40.9 6,341 34.1 66,641 27.2
Year of cancer 
diagnosis
1998 8 0.1 5,781 4.5 5,691 6.2 252 1.4 11,732 4.8
1999 153 2.2 5,949 4.7 5,747 6.2 295 1.6 12,144 4.9
2000 185 2.6 6,535 5.1 5,834 6.3 375 2.0 12,929 5.3
2001 240 3.4 6,767 5.3 5,970 6.5 486 2.6 13,463 5.5
2002 257 3.7 7,088 5.5 5,739 6.2 507 2.7 13,591 5.5
2003 240 3.4 7,112 5.6 5,224 5.7 602 3.2 13,178 5.4
2004 272 3.9 7,364 5.8 5,369 5.8 724 3.9 13,729 5.6
2005 344 4.9 7,984 6.2 5,169 5.6 660 3.6 14,157 5.8
2006 447 6.4 7,671 6.0 5,199 5.6 830 4.5 14,147 5.8
2007 460 6.6 7,948 6.2 5,283 5.7 1,028 5.5 14,719 6.0
2008 466 6.6 7,837 6.1 5,371 5.8 1,223 6.6 14,897 6.1
2009 515 7.3 7,561 5.9 5,180 5.6 1,443 7.8 14,699 6.0
2010 482 6.9 7,749 6.1 5,199 5.6 1,574 8.5 15,004 6.1
2011 630 9.0 7,941 6.2 5,064 5.5 1,748 9.4 15,383 6.3
2012 626 8.9 7,660 6.0 4,987 5.4 1,856 10.0 15,129 6.2
2013 686 9.8 7,443 5.8 4,715 5.1 2,115 11.4 14,959 6.1
2014 692 9.9 7,421 5.8 4,166 4.5 1,930 10.4 14,209 5.8
2015 312 4.4 3,955 3.1 2,155 2.3 927 5.0 7,349 3.0
Reporting hospital 
was National 
Cancer Institute-
designated cancer 
center
No 6,734 96.0 120,670 94.4 87,958 95.5 17,284 93.0 232,646 94.8
Yes 281 4.0 7,096 5.6 4,104 4.5 1,291 7.0 12,772 5.2
SES of hospital’s 
patient 
distribution
Low: ≥50% lowest 
2 quintiles, <50% 
highest 2 1,039 14.8 19,554 15.3 20,401 22.2 2,636 14.2 43,630 17.8
Medium: neither 
low nor high 2,102 30.0 36,918 28.9 29,909 32.5 4,812 25.9 73,741 30.0
High: ≥50% highest 
2 quintiles, <50% 
lowest 2 3,871 55.2 71,275 55.8 41,744 45.3 11,124 59.9 128,014 52.2
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Surgical Procedures
All Patients
Breast conserving
surgery without
radiation (in
patients aged ≥70,
stage I, ER/PR-
positive, and
HER2-negative)
Breast conserving
therapy (surgery
with radiation)
Unilateral
mastectomy
Bilateral
mastectomy
N
Column 
% N
Column 
% N
Column 
% N
Column 
% N
Column 
%
<5 cancer patients 
at facility <5 19 0.0 8 0.0 <5 33 0.0
Adjuvant 
chemotherapy
No 6,939 98.9 90,238 70.6 54,318 59.0 10,255 55.2 161,750 65.9
Yes 76 1.1 37,528 29.4 37,744 41.0 8,320 44.8 83,668 34.1
Adjuvant radiation
No 7,015 100.0 0 0.0 75,201 81.7 15,419 83.0 97,635 39.8
Yes 0 0.0 127,766 100.0 16,861 18.3 3,156 17.0 147,783 60.2
Breast cancer 
outcomes
Subsequent 
contralateral breast 
cancer (BC) 143 2.0 4,213 3.3 3,384 3.7 44 0.2 7,784 3.2
Subsequent 
ipsilateral BC 88 1.3 2,387 1.9 310 0.3 93 0.5 2,878 1.2
Subsequent bilateral 
BC 0 0.0 <5 0 0.0 <5 <5
Subsequent BC, 
laterality unknown 0 0.0 19 0.0 28 0.0 <5 51 0.0
Died of breast 
cancer 152 2.2 5,296 4.1 10,178 11.1 983 5.3 16,609 6.8
Died of other cause 1,905 27.2 12,346 9.7 13,519 14.7 575 3.1 28,345 11.5
Died of unknown 
cause 24 0.3 446 0.3 602 0.7 40 0.2 1,112 0.5
Lost to follow up 
before 12/31/2015 
(study end) 538 7.7 10,090 7.9 8,987 9.8 1,474 7.9 21,089 8.6
Followed until 
12/31/2015 4,165 59.4 92,968 72.8 55,054 59.8 15,361 82.7 167,548 68.3
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Table 2.
Associations with risk of second contralateral breast cancer with 95% confidence intervals (CI) among breast 
cancer patients stages 0-III, 1998-2015, California*
Hazard Ratio
Lower
95% CI
Upper
95% CI p-value
Surgical procedure
Breast conserving therapy: surgery with radiation (BCT, reference) 1.00 - - -
Breast conserving surgery without radiation (BCS): restricted to age ≥70, stage I, estrogen/
progesterone receptor (ER/PR)-positive and HER2-negative
0.91 0.77 1.08 0.30
Unilateral mastectomy (ULM) 1.07 1.02 1.13 0.0081
Bilateral mastectomy (BLM) 0.10 0.07 0.14 <0.0001
Race/ethnicity
Non-Hispanic (NH) White (reference) 1.00 - - -
NH Black 1.23 1.13 1.35 <0.0001
Hispanic 1.00 0.94 1.07 0.97
Chinese 1.12 0.97 1.30 0.13
Japanese 1.00 0.81 1.22 0.97
Filipina 1.30 1.17 1.44 <0.0001
Other Asian/Pacific Islander ethnicity 1.02 0.90 1.16 0.77
Age at diagnosis, years
<40 1.16 1.05 1.29 0.0034
40-49 0.96 0.91 1.02 0.20
50-64 (reference) 1.00 - - -
≥65 0.90 0.84 0.96 0.0024
Marital status at diagnosis
Married (reference) 1.00 - - -
Unmarried 1.01 0.96 1.06 0.71
Neighborhood socioeconomic status (SES), quintiles
First (lowest) quintile (reference) 1.00 - - -
Second quintile 0.94 0.85 1.04 0.23
Third quintile 0.93 0.84 1.02 0.14
Fourth quintile 1.00 0.91 1.10 0.99
Fifth (highest) quintile 0.97 0.88 1.06 0.48
Insurance status
Private only (reference) 1.00 - - -
No insurance 1.08 0.85 1.36 0.54
Medicare with or without private 0.98 0.91 1.04 0.46
Any Medicaid, military or other public 0.92 0.85 1.00 0.06
Stage
0 1.41 1.29 1.54 <0.0001
I (reference) 1.00 - - -
II 0.92 0.86 0.98 0.02
III 0.99 0.88 1.11 0.81
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Hazard Ratio
Lower
95% CI
Upper
95% CI p-value
Tumor size (per centimeter increase) 1.01 1.00 1.02 0.06
Tumor grade
Grade 1 (reference) 1.00 - - -
Grade 2 0.97 0.91 1.02 0.23
Grade 3 0.93 0.86 0.99 0.04
Tumor histology
Ductal (reference) 1.00 - - -
Lobular 1.00 0.91 1.10 0.94
Other 0.99 0.91 1.07 0.75
Estrogen/progesterone receptors (ER/PR)
Either positive (reference) 1.00 - - -
Both negative 1.30 1.21 1.39 <0.0001
Lymph node involvement
Negative (reference) 1.00 - - -
Positive 0.94 0.88 1.02 0.14
Year of diagnosis (per 1-year increase) 0.97 0.97 0.98 <0.0001
Reporting hospital National Cancer Institute-designated cancer center
No (reference) 1.00 - - -
Yes 0.98 0.85 1.12 0.72
SES of hospital’s patient distribution
High: ≥50% highest 2 quintiles, <50% lowest 2 (reference) 1.00 - - -
Low: ≥50% lowest 2 quintiles, <50% highest 2 0.99 0.91 1.07 0.73
Medium: neither low nor high 0.98 0.92 1.04 0.45
Adjuvant therapy (chemotherapy and/or radiation)
No (reference) 1.00 - - -
Yes 0.93 0.88 0.99 0.03
Stratified Models
Surgical procedures by age category at diagnosis**
Age <50 years
BCT (reference) 1.00 - - -
ULM 0.99 0.89 1.09 0.77
BLM 0.09 0.05 0.15 <0.0001
Age ≥50 years
BCS: age ≥70, stage I, ER/PR-positive, HER2-negative 0.88 0.74 1.04 0.14
BCT (reference) 1.00 - - -
ULM 1.11 1.05 1.18 0.0003
BLM 0.11 0.07 0.18 <0.0001
Surgical procedures by grade categories†
Grade 1 or 2
BCS: age ≥70, stage I, ER/PR-positive, HER2-negative 0.86 0.71 1.05 0.13
BCT (reference) 1.00 - - -
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Hazard Ratio
Lower
95% CI
Upper
95% CI p-value
ULM 1.10 1.03 1.18 0.003
BLM 0.07 0.04 0.13 <0.0001
Grade 3
BCS: age ≥70, stage I, ER/PR-positive, HER2-negative 1.10 0.63 1.91 0.73
BCT (reference) 1.00 - - -
ULM 1.02 0.93 1.10 0.72
BLM 0.14 0.09 0.22 <0.0001
Surgical procedures by ER/PR categories‡
ER/PR-negative
BCT (reference) 1.00 - - -
ULM 1.02 0.90 1.15 0.78
BLM 0.13 0.07 0.23 <0.0001
ER/PR-positive
BCS: age ≥70, stage I, ER/PR-positive, HER2-negative 0.92 0.77 1.09 0.34
BCT (reference) 1.00 - - -
ULM 1.11 1.04 1.18 0.002
BLM 0.09 0.06 0.15 <0.0001
*
Fine and Gray regression model with death as a competing risk, adjusted for the variables in the table.
**
P interaction=0.09 for the global test of an interaction between age and surgical procedure from a fully adjusted model additionally adjusted for 
statistically significant interactions with age (race, insurance type, stage, hormone receptor status, diagnosis year, and adjuvant treatment). 
Individual interaction terms were p=0.03 for ULM and p=0.48 for BLM
†
P-interaction=0.06 for the global test of an interaction between grade and surgical procedure from a fully adjusted model additionally adjusted for 
statistically significant interactions with grade (race and lymph node involvement). Individual interaction terms were p=0.57 for BCS, p=0.20 for 
ULM, and p=0.03 for BLM
‡
P-interaction=0.15 for the global test of an interaction between ER/PR status and surgical procedure from a fully adjusted model additionally 
adjusted for statistically significant interactions with ER/PR status (race and stage). Individual interaction terms were p=0.11 for ULM and p=0.35 
for BLM
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Table 3.
Absolute excess risk of second contralateral breast cancer, shown as excess cases per 10,000 person-years 
among breast cancer patients of stages 0-III relative to the general population, 1998-2015, California*
Observed Expected
Person-
years, total
Absolute
Excess Risk
Surgical procedure
Breast conserving surgery without radiation (BCS): restricted to age ≥70, stage I, 
estrogen/progesterone receptor (ER/PR)-positive and HER2-negative
143 145 32,384 −0.7
Breast-conserving therapy: surgery with radiation (BCT) 4,213 3,755 918,682 5.0
Unilateral mastectomy (ULM) 3,384 2,517 639,370 13.6
Bilateral mastectomy (BLM) 44 327 99,017 −28.6
Age at first breast cancer diagnosis, years
<50 1,905 1,066 436,687 19.2
≥50 5,879 5,678 1,252,767 1.6
Tumor grade
1 or 2 4,675 4,349 1,059,270 3.1
3 2,641 1,999 534,040 12.0
Estrogen and progesterone receptors (ER/PR)
Both negative 1,320 858 228,891 20.2
Either positive 5,229 4,979 1,236,805 2.0
Surgical procedures by age category at diagnosis
Age <50 years
BCT 976 531 210,551 21.2
ULM 911 435 179,820 26.5
BLM 18 101 46,315 −17.9
Age ≥50 years
BCS: age ≥70, stage I, ER/PR-positive, HER2-negative 143 145 32,384 −0.7
BCT 3,237 3,224 708,131 0.2
ULM 2,473 2,082 459,550 8.5
BLM 26 226 52,702 −38.0
Surgical procedures by grade categories
Grade 1 or 2
BCS: age ≥70, stage I, ER/PR-positive, HER2-negative 121 128 28,568 −2.5
BCT 2,706 2,570 614,130 2.2
ULM 1,832 1,456 359,800 10.4
BLM 16 194 56,772 −31.4
Grade 3
BCS: age ≥70, stage I, ER/PR-positive, HER2-negative 13 12 2,556 5.8
BCT 1,285 993 258,663 11.3
ULM 1,319 886 237,151 18.3
BLM 24 109 35,670 −23.9
Surgical procedures by ER/PR categories
ER/PR-negative
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Observed Expected
Person-
years, total
Absolute
Excess Risk
BCT 649 431 113,063 19.2
ULM 660 381 101,009 27.7
BLM 11 46 14,819 −23.4
ER/PR-positive
BCS: age ≥70, stage I, ER/PR-positive, HER2-negative 143 145 32,384 −0.7
BCT 2,950 2,871 696,214 1.1
ULM 2,109 1,723 435,820 8.9
BLM 27 240 72,387 −29.5
*Age- and calendar period-adjusted
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Table 4.
Associations with risk of breast cancer death with 95% confidence intervals (CI) among breast cancer patients 
stages 0-III, 1998-2015, California*
Hazard
Ratio
Lower
95% CI
Upper
95% CI p-value
Surgical procedure
Breast conserving therapy with radiation (reference) 1.00 - - -
Breast conserving surgery without radiation: restricted to age ≥70, stage I, estrogen/progesterone 
receptor (ER/PR)-positive and HER2-negative
1.36 1.16 1.59 0.0001
Unilateral mastectomy 1.21 1.17 1.25 <0.0001
Bilateral mastectomy 1.03 0.96 1.11 0.35
Age at first breast cancer diagnosis, years
<40 (reference) 1.00 - - -
40-49 0.78 0.73 0.83 <0.0001
50-64 0.79 0.74 0.84 <0.0001
≥65 0.93 0.87 0.99 0.03
Race/ethnicity
Non-Hispanic (NH) White (reference) 1.00 - - -
NH Black 1.21 1.14 1.28 <0.0001
Hispanic 0.92 0.88 0.96 0.0004
Chinese 0.84 0.75 0.93 0.0006
Japanese 0.81 0.69 0.94 0.0062
Filipina 0.86 0.79 0.93 0.0003
Other Asian/Pacific Islander ethnicity 0.86 0.79 0.93 0.0003
Marital status at diagnosis
Married (reference) 1.00 - - -
Unmarried 1.09 1.06 1.13 <0.0001
Neighborhood socioeconomic status (SES), quintiles
First (lowest) quintile (reference) 1.00 - - -
Second quintile 1.02 0.97 1.08 0.41
Third quintile 0.97 0.92 1.03 0.33
Fourth quintile 0.95 0.89 1.00 0.06
Fifth (highest) quintile 0.87 0.82 0.93 <0.0001
Insurance status
Private only (reference) 1.00 - - -
No insurance 1.20 1.04 1.39 0.013
Medicare with or without private 1.25 1.19 1.32 <0.0001
Any Medicaid, military or other public 1.30 1.24 1.36 <0.0001
Tumor grade
Grade 1 (reference) 1.00 - - -
Grade 2 1.79 1.68 1.90 <0.0001
Grade 3 2.73 2.55 2.91 <0.0001
Tumor histology
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Hazard
Ratio
Lower
95% CI
Upper
95% CI p-value
Ductal (reference) 1.00 - - -
Lobular 1.06 1.00 1.12 0.06
Other 0.73 0.68 0.79 <0.0001
Estrogen/progesterone receptors (ER/PR)
Either positive (reference) 1.00 - - -
Both negative 1.55 1.49 1.61 <0.0001
Lymph node involvement
Negative (reference) - - - -
Positive 1.97 1.88 2.06 <0.0001
Reporting hospital National Cancer Institute-designated cancer center
No (reference) 1.00 - - -
Yes 0.89 0.83 0.97 0.005
SES of hospital’s patient distribution
High: ≥50% highest 2 quintiles, <50% lowest 2 (reference) 1.00 - - -
Medium: neither low nor high 1.09 1.05 1.13 <0.0001
Low: ≥50% lowest 2 quintiles, <50% highest 2 1.08 1.03 1.14 0.0016
Adjuvant therapy (chemotherapy and/or radiation)
No (reference) 1.00 - - -
Yes 1.12 1.08 1.17 <0.0001
*
Fine and Gray regression model with death from another cause as a competing risk, stratified by stage, tumor size and year of diagnosis and 
adjusted for the variables in the table. N=1,150 with unknown cause of death were excluded.
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